This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ViroPharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript

As you know forward-looking statements are subject to factors that may cause our results and plans to materially differ from those expected. Please refer to the press release issued this morning and to our filings with the SEC for more information regarding the risks and uncertainties that could cause future results to differ materially from those expectations expressed in this conference call.

In this call, we will also discuss some non-GAAP measures in talking about our Company’s performance and you can find the reconciliation of those measures to GAAP measures in our press release issued this morning.

I’ll now turn the call back over to Vin.

Vincent J. Milano

Thanks, Pete. As you may recall, we provided our last update in May. I spoke of how we viewed the entry of generic Vancocin, as the opportunity for new beginning of positive strong growth and momentum for ViroPharma. I am very pleased to be providing you with an update this morning that eliminates any doubt about the positive direction we believe our company is heading throughout the rest of 2012 and beyond.

The agenda for today’s call is that I will provide an overview of the company’s recent progress, Charlie will then provide the financial overview of the quarter and I will return for a few closing comments before taking your questions.

For some areas of the company, our comments will be brief as we are preparing more robust content for our Analyst Day on September 21. We plan to distribute the formal invitation through this event next week.

As we reported a few days ago, the FDA approved our prior accrual supplement for industrial scale manufacturing of Cinryze. We believe this approval paves the way for us to provide for and ensure that any patient who can benefit from Cinryze has access to an uninterrupted supply.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs